Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 587 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial,... July 11, 2023 Changing the landscape of children’s cancer treatment September 2, 2020 What to Know About Exercising During Prostate Cancer: An Expert Q&A August 8, 2023 EMA Recommends Granting a Marketing Authorisation for Ivosidenib March 1, 2023 Load more HOT NEWS Ending smoking could more than halve England’s cancer inequality gap Breast Cancer Patient Given 2 Years to Live is Now a... Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... A Penny for Your Thoughts
